Pay in 4 interest-free payments of $7.22 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
LY3298176 has the potential to deliver clinically meaningful improvement in glycaemic control and body weight
Understanding the primary FDA-approved purpose of each medication is the easiest way to narrow down your options
Until now, Medicare by law couldnt cover drugs prescribed solely for weight loss
Table 1: Patient demographics Reasons for discontinuation Across the entire population, side effects were the leading reason patients stopped taking GLP-1 RAs, accounting for 28.2% of all discontinuations (Table 2)
US$ 20.35
US$ 27.17
US$ 28.09
